Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$13.84 +9.7%	$14.25	$7.05 ▼ $17.15	$363.30M	0.37	56,645 shs	113,093 shs
ENTX Entera Bio	$1.83 +2.8%	$2.01	$1.41 ▼ $2.79	$83.17M	1.46	67,361 shs	32,962 shs
OLMA Olema Pharmaceuticals	$4.99 +7.8%	$4.62	$2.86 ▼ $16.62	$341.42M	1.9	822,937 shs	456,999 shs
RGNX REGENXBIO	$9.17 +4.9%	$8.96	$5.04 ▼ $15.36	$459.97M	1.06	928,068 shs	552,178 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-6.45%	+4.21%	-21.13%	+3.70%	+30.51%
ENTX Entera Bio	-2.73%	-4.30%	-14.01%	+7.85%	+0.56%
OLMA Olema Pharmaceuticals	+4.04%	+5.95%	+3.81%	+46.98%	-57.99%
RGNX REGENXBIO	+3.68%	+6.20%	-9.05%	+47.88%	-17.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	2.1669 of 5 stars	3.6	2.0	0.0	3.1	0.8	0.0
ENTX Entera Bio	2.2371 of 5 stars	3.5	5.0	0.0	0.6	0.8	0.0
OLMA Olema Pharmaceuticals	1.7319 of 5 stars	3.5	1.0	0.0	0.0	2.5	0.6
RGNX REGENXBIO	4.4835 of 5 stars	3.4	3.0	4.6	2.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.20	Buy	$23.83	72.21% Upside
ENTX Entera Bio	3.00	Buy	$10.00	446.45% Upside
OLMA Olema Pharmaceuticals	3.00	Buy	$24.50	390.98% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	244.87% Upside

Current Analyst Ratings Breakdown

Latest ENTX, RGNX, OLMA, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/14/2025	OLMA Olema Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
5/14/2025	OLMA Olema Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $22.00
4/28/2025	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/10/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$18.00 ➝ $20.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$4.68 per share	N/A
ENTX Entera Bio	$180K	462.08	N/A	N/A	$0.23 per share	7.96
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$7.14 per share	N/A
RGNX REGENXBIO	$156.72M	2.93	N/A	N/A	$5.24 per share	1.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
ENTX Entera Bio	-$9.54M	-$0.26	N/A	N/A	N/A	-4,525.11%	-95.10%	-82.77%	8/8/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$2.01	N/A	N/A	N/A	N/A	-42.31%	-38.32%	8/5/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)

Latest ENTX, RGNX, OLMA, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.44	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/13/2025	Q1 2025	OLMA Olema Pharmaceuticals	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/9/2025	Q1 2025	ENTX Entera Bio	-$0.07	-$0.06	+$0.01	-$0.06	N/A	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	14.80	14.80
ENTX Entera Bio	N/A	13.07	13.07
OLMA Olema Pharmaceuticals	N/A	15.22	15.22
RGNX REGENXBIO	N/A	2.93	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
ENTX Entera Bio	14.11%
OLMA Olema Pharmaceuticals	91.78%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	1.30%
ENTX Entera Bio	10.38%
OLMA Olema Pharmaceuticals	16.36%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
ENTX Entera Bio	20	45.45 million	40.73 million	Optionable
OLMA Olema Pharmaceuticals	70	68.42 million	57.23 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable

ENTX, RGNX, OLMA, and BNTC Headlines

Recent News About These Companies

RGNX | REGENXBIO Inc. Annual Income Statement - MarketWatch

July 6 at 2:10 AM | marketwatch.com

Janney Montgomery Scott LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)

July 4, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

June 30, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 16, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Stock Price Up 6.1% - What's Next?

June 11, 2025 | marketbeat.com

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts

June 9, 2025 | benzinga.com

REGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan Capital

June 9, 2025 | marketbeat.com

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

June 6, 2025 | seekingalpha.com

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

June 6, 2025 | biopharmadive.comB

RegeNXBio shares fall, despite positive new data on RGX-202

June 6, 2025 | thepharmaletter.comT

Regenxbio’s Duchenne gene therapy data positive as shares falter

June 5, 2025 | bioworld.comB

Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy

June 5, 2025 | biospace.comB

REGENXBIO updates Phase 1/2 data for Duchenne candidate

June 5, 2025 | msn.com

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

June 5, 2025 | benzinga.com

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

June 5, 2025 | prnewswire.com

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

June 2, 2025 | prnewswire.com

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress

May 22, 2025 | investing.com

REGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 20, 2025 | finanznachrichten.de

REGENXBIO announces royalty monetization agreement for up to $250M

May 20, 2025 | msn.com

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 19, 2025 | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in Stock

May 15, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, RGNX, OLMA, and BNTC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$13.84 +1.22 (+9.67%)

As of 04:00 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Entera Bio NASDAQ:ENTX

$1.83 +0.05 (+2.81%)

As of 03:52 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Olema Pharmaceuticals NASDAQ:OLMA

$4.99 +0.36 (+7.78%)

As of 04:00 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

REGENXBIO NASDAQ:RGNX

$9.17 +0.43 (+4.92%)

Closing price 04:00 PM Eastern

Extended Trading

$9.19 +0.02 (+0.17%)

As of 05:55 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time